Autoimmune disorder of blood
MONDO:0000602A hypersensitivity reaction type II disease that involves the blood.
Also known as: blood autoimmune disease, blood hypersensitivity reaction type II disease
205 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Fetal stem cells aim to tame immune chaos
Disease control ENROLLING_BY_INVITATIONThis early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for chronic blood disorder: combo therapy aims to keep platelets stable
Disease control OngoingThis study tests whether adding ianalumab to standard eltrombopag treatment helps adults with immune thrombocytopenia (ITP) who did not get better with steroids. ITP causes low platelet counts, raising bleeding risk. The trial involves 152 participants and measures how long the t…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New biologic aims to stabilize platelet counts in ITP patients
Disease control OngoingThis phase 3 trial tests whether adding ianalumab (a biologic drug) to standard corticosteroids helps adults with newly diagnosed immune thrombocytopenia (ITP) achieve a stable platelet response off all treatments at 12 months. About 226 participants will receive either ianalumab…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare blood disorder: drug trial targets anemia
Disease control OngoingThis phase 3 trial tests a drug called ianalumab against a placebo in 90 adults with warm autoimmune hemolytic anemia (wAIHA) who have already tried at least one treatment without success. The goal is to see if ianalumab can raise hemoglobin levels and keep them stable for at lea…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug M281 aims to tame rare blood disorder
Disease control OngoingThis study tests an experimental drug called M281 (Nipocalimab) in adults with warm autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. The trial compares M281 to a placebo to see if it can improve hemoglobin levels and reduce fatigue. About …
Phase: PHASE2, PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill could help patients with rare blood disorder
Disease control OngoingThis study tests an experimental drug called rilzabrutinib in 22 adults with warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. Participants take the drug daily for up to 24 weeks, with an option to continue longer. The main goa…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental CAR-T therapy targets tough autoimmune conditions
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new type of CAR-T cell therapy in 9 people with autoimmune diseases that have not responded well to standard treatments. The therapy uses specially engineered immune cells to target and attack faulty immune cells. The main goal is to check safety an…
Phase: EARLY_PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Stem cell trial for rare bleeding disorder pulled before it began
Disease control TerminatedThis study planned to test whether infusions of mesenchymal stem cells could safely help people with refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial was withdrawn before enrolling any participants, so n…
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for warm AIHA: drug trial targets blood cell destruction
Disease control OngoingThis study tests a drug called HMPL-523 (Sovleplenib) in people with warm antibody autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. About 111 adults will receive either the drug or a placebo to see if it improves hemoglobin levels and cont…
Phase: PHASE2, PHASE3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a cancer drug tame a blood disorder?
Disease control OngoingThis phase 2 trial tests the drug acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have a blood condition called autoimmune hemolytic anemia (AIHA) that has come back or not responded to treatment. The study aims to see if acalabrutinib can control the ane…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug aims to stop transplant attack on the body
Disease control OngoingThis phase 2 trial tests whether the drug itacitinib, given with standard care, can prevent graft-versus-host disease (GVHD) in people who receive a donor stem cell transplant for blood cancers. GVHD happens when the donor cells attack the patient's body. The study includes 31 ad…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for ITP patients: experimental drug aims to boost platelets
Disease control OngoingThis phase 2 trial tests an experimental drug called ianalumab in 41 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants have already tried steroids and another standard treatment. The study mea…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a cancer drug fix blood cell problems after transplant?
Disease control OngoingThis phase 2 trial tests whether isatuximab can help people whose blood cell counts stay low after a stem cell transplant for blood cancer. The study enrolls 12 adults whose disease is in remission but who have developed immune-related blood cell deficiencies. Participants receiv…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug hope for rare blood disorder that causes anemia in cold weather
Disease control OngoingThis phase 2 trial tests the drug zanubrutinib (Brukinsa) in 25 people with primary cold agglutinin disease, a rare condition where the immune system attacks red blood cells in cold temperatures, causing anemia and poor circulation. The study aims to see if the drug can reduce an…
Phase: PHASE2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy shows promise for rare bleeding disorder
Disease control OngoingThis study tests whether adding diammonium glycyrrhizinate (a liver-protecting compound) to standard high-dose dexamethasone can improve platelet counts in adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing b…
Phase: PHASE2 • Sponsor: Shandong University • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Drug access program offers hope for rare blood disorder patients
Disease control TEMPORARILY_NOT_AVAILABLEThis program provides continued treatment with nipocalimab for people with warm autoimmune hemolytic anemia (wAIHA) who have already shown improvement in a previous study. Participants receive the drug by IV infusion every 2 or 4 weeks. The goal is to keep their hemoglobin levels…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New shot shows promise for long-term platelet control in rare bleeding disorder
Disease control OngoingThis study tests a drug called efgartigimod given as a shot under the skin for adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The goal is to see if the drug is safe and helps maintain safe platele…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Study withdrawn: extended access to fostamatinib for transplant patients never launched
Disease control TerminatedThis study was designed to give people who had a stem cell transplant and developed low blood cell counts (anemia, low platelets) continued access to the drug fostamatinib. Only those who responded well in a prior study were eligible. The goal was to see if they could maintain st…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New oral drug shows promise for Long-Term control of rare bleeding disorder
Disease control OngoingThis study is for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. It tests the long-term safety and benefit of an oral drug called rilzabrutinib. Only 4 participants who already benefited fr…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising ITP drug trial pulled before it even started
Disease control TerminatedThis study was designed to test the safety and tolerability of a new drug called HMPL-523 (sovleplenib) in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The trial was withdrawn before enrolling any pa…
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 26, 2026 18:23 UTC
-
Could listening to music ease the stress of stem cell transplants?
Symptom relief OngoingThis pilot study tests whether a daily mindful music listening program is practical and acceptable for patients hospitalized after an allogeneic stem cell transplant. About 35 adults will listen to music for one hour each day using a web-based platform. The study measures how fea…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Art and exercise may boost recovery for kids after transplant
Symptom relief OngoingThis study looks at whether adding art therapy to physical therapy can help children aged 5 to 18 recover emotionally and physically after a stem cell transplant. For two weeks, some children receive both art and physical therapy daily, while others get only physical therapy. Res…
Phase: NA • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New registry aims to unlock safer pregnancies for women with autoimmune conditions
Knowledge-focused ENROLLING_BY_INVITATIONThis registry enrolls up to 1,000 women aged 12–55 with rheumatic or autoimmune diseases who are pregnant or planning pregnancy. Researchers will collect data from medical records and patient surveys to study pregnancy outcomes, disease activity, and medication use. No experiment…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Did storing testicular tissue as a child protect fertility? new study aims to find out
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 50 young men who had cancer or blood disorders as children and received treatments that can harm fertility. Some stored testicular tissue before treatment; others did not. Researchers will check their fertility through exams, ultrasounds, blood tests, and semen…
Phase: NA • Sponsor: Universitair Ziekenhuis Brussel • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New registry aims to unlock secrets of rare blood disorder
Knowledge-focused OngoingThis study is a registry that collects information from about 429 adults with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS), a rare condition where the immune system attacks red blood cells in cold temperatures. Researchers will track symptoms, treatments, compl…
Sponsor: RECORDATI GROUP • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Immune cell showdown: autoimmune vs. infection vs. healthy
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC